Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary Stents
The Dual Antiplatelet Therapy Randomized Clinical Trial

Dean J. Kereiakes, MD; Robert W. Yeh, MD; Joseph M. Massaro, PhD; Priscilla Driscoll-Shempp, MBA; Donald E. Cutlip, MD; P. Gabriel Steg, MD; Anthony H. Gershlick, MD; Harald Darius, MD; Ian T. Meredith, MD, PhD; John Ormiston, MD; Jean Francois Tanguay, MD; Adrian Corneliu Iancu, MD; Jaroslav Trebacz, MD, PhD; Laura Mauri, MD; for the Dual Antiplatelet Therapy (DAPT) Study Investigators

IMPORTANCE Despite antirestenotic efficacy of coronary drug-eluting stents (DES) compared with bare metal stents (BMS), the relative risk of stent thrombosis and adverse cardiovascular events is unclear. Although dual antiplatelet therapy (DAPT) beyond 1 year provides ischemic event protection after DES, ischemic event risk is perceived to be less after BMS, and the appropriate duration of DAPT after BMS is unknown.

OBJECTIVE To compare (1) rates of stent thrombosis and major adverse cardiac and cerebrovascular events (MACCE; composite of death, myocardial infarction, or stroke) after 30 vs 12 months of thienopyridine in patients treated with BMS taking aspirin and (2) treatment duration effect within the combined cohorts of randomized patients treated with DES or BMS as prespecified secondary analyses.

DESIGN, SETTING, AND PARTICIPANTS International, multicenter, randomized, double-blinded, placebo-controlled trial comparing extended (30-months) thienopyridine vs placebo in patients taking aspirin who completed 12 months of DAPT without bleeding or ischemic events after receiving stents. The study was initiated in August 2009 with the last follow-up visit in May 2014.

INTERVENTIONS Continued thienopyridine or placebo at months 12 through 30 after stent placement, in 11,648 randomized patients treated with aspirin, of whom 1,687 received BMS and 9,961 DES.

MAIN OUTCOMES AND MEASURES Stent thrombosis, MACCE, and moderate or severe bleeding.

RESULTS Among 1,687 patients treated with BMS who were randomized to continued thienopyridine vs placebo, rates of stent thrombosis were 0.5% vs 1.1% (n = 4 vs 9; hazard ratio [HR], 0.49; 95% CI, 0.15-1.64; P = .24), rates of MACCE were 4.04% vs 4.69% (n = 33 vs 38; HR, 0.92; 95% CI, 0.57-1.47; P = .72), and rates of moderate/severe bleeding were 2.03% vs 0.90% (n = 16 vs 7; P = .07), respectively. Among all 11,648 randomized patients (both BMS and DES), stent thrombosis rates were 0.41% vs 1.32% (n = 23 vs 74; HR, 0.31; 95% CI, 0.19-0.50; P < .001), rates of MACCE were 4.29% vs 5.74% (n = 244 vs 323; HR, 0.73; 95% CI, 0.62-0.87; P < .001), and rates of moderate/severe bleeding were 2.45% vs 1.47% (n = 135 vs 80; P < .001).

CONCLUSIONS AND RELEVANCE Among patients undergoing coronary stent placement with BMS and who tolerated 12 months of thienopyridine, continuing thienopyridine for an additional 18 months compared with placebo did not result in statistically significant differences in rates of stent thrombosis, MACCE, or moderate or severe bleeding. However, the BMS subset may have been underpowered to identify such differences, and further trials are suggested.

TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00977938


Last corrected on July 5, 2016.
Current clinical practice guidelines recommend a minimum of only 1 month of dual antiplatelet therapy (DAPT) after bare metal stent (BMS) placement following elective percutaneous coronary intervention (PCI), compared with 6 to 12 months for drug-eluting stents (DES), and patients with acute coronary syndromes benefit from 12 months of therapy whether or not PCI with stent placement is performed. Although randomized trial results showed a reduction in stent thrombosis and non–stent-related myocardial infarction (MI) with thienopyridine therapy beyond 12 months after DES placement (among patients tolerating DAPT to 12 months), few trials have assessed optimal duration of DAPT after BMS.

Methods

We compared the randomized treatment effect of continuing to receive thienopyridine vs receiving placebo beyond 12 months with regard to stent thrombosis, MACCE, and bleeding after randomization until the completion of study drug treatment at 30 months among patients treated with BMS as well as the combined cohort of patients treated with BMS or DES. As a prespecified analysis, we assessed the consistency of treatment duration effect between patients treated with BMS and (2) treatment duration effect among all randomized patients treated with BMS or DES.

Study Design

The DAPT Study design has previously been described. This double-blind, international, randomized clinical trial compared the risks and benefits of continued thienopyridine (clopidogrel or prasugrel) vs placebo, when given in addition to aspirin for the prevention of stent thrombosis or MACCE after coronary stent placement with either DES or BMS in patients who tolerated DAPT to 12 months. The results comparing randomized treatments in the DES-treated cohort have been reported separately. All institutions received approval from their institutional review boards, and each patient provided written informed consent for study participation.

Study Population and Procedures

In brief, patients who were candidates for DAPT and who received treatment with either DES or BMS were recruited. Stent treatment was performed according to site standards of care using only US Food and Drug Administration–approved DES and BMS devices. Types of DES included Cypher sirolimus-eluting stent (Cordis), Endeavor zotarolimus-eluting stent (Medtronic), TAXUS paclitaxel-eluting stent (Boston Scientific), and Xience/Promus everolimus-eluting stents (Abbott Vascular or Boston Scientific). All patients older than 18 years who met all enrollment inclusion and none of the exclusion criteria (eTable 1 in the Supplement) and signed the consent were enrolled into the trial within 3 days of the index procedure, and all received open-label aspirin plus thienopyridine for the first 12 months. As permitted by regulatory authorities, race and ethnicity data were collected via patient self-report. Race categories for this study were prespecified as American Indian or Alaska Native, Asian, black or African American, Native Hawaiian or other Pacific Islander, white, and other. Ethnicity was collected as Hispanic or Latino and not Hispanic or Latino.

At 12 months, patients who were alive and free from MI, stroke, repeat coronary revascularization, stent thrombosis, and moderate or severe bleeding and who demonstrated adherence with thienopyridine treatment were then eligible for randomization (Figure) to continue receiving thienopyridine or to receive placebo, and all continued aspirin. A computergenerated randomization schedule stratified patients according to the type of stent they had received (DES vs BMS), hospital site, thienopyridine type, and presence or absence of at least 1 prespecified clinical- or lesion-related risk factor for stent thrombosis (eTable 2 in the Supplement). Postrandomization study procedures and follow-up were the same for all patients regardless of whether they had BMS or DES.

Study End Points

The co-primary effectiveness end points were cumulative incidence of definite or probable stent thrombosis according to the Academic Research Consortium classification and incidence of MACCE at 12 to 30 months. For randomized comparison of DAPT duration among patients treated with BMS, the primary safety end point was moderate or severe bleeding (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries [GUSTO] classification) at 12 to 30 months. Finally, clinically actionable bleeding not related to coronary artery bypass graft procedures was also evaluated according to the Bleeding Academic Research Consortium definitions (BARC type 2, 3, or 5).

These events were adjudicated by an independent clinical events committee blinded to treatment assignment and administered by the Harvard Clinical Research Institute (HCR). An unblinded independent central data monitoring committee oversaw the safety of all patients.

Statistical Analysis

Among patients treated with BMS and randomized to continued thienopyridine vs placebo, the cumulative incidence of stent thrombosis and of MACCE are presented according to intention-to-treat. Treatments were compared using a log-rank test stratified by geographic region (North America, Europe, and Australia/New Zealand), thienopyridine type, and pres-
ence or absence of stent thrombosis risk factors (Table 1). For each end point, the stratified hazard ratio (HR) and its 2-sided 95% CI comparing continued thienopyridine vs placebo are presented. Patients not experiencing the co-primary end points at 12 to 30 months after the index procedure were censored at the time of last known contact or 30 months, whichever was earlier.

The analysis of the BMS cohort comparing randomized treatment groups was a prespecified secondary analysis of the DAPT Study that was not powered to compare treatment groups within this cohort (the powered DES-treated cohort has been previously presented) but was performed to assess consistency of the randomized treatment effect among patients treated with BMS vs DES from the DAPT Study. As a prespecified analysis, stent type × randomized treatment interaction was assessed using Cox proportional hazards regression for ischemic events and logistic regression for bleeding events; stratified HR for ischemic events and non-stratified risk difference for bleeding events, their 95% CI, and P values for interaction are presented. All other analyses presented were prespecified.

All statistical analyses were conducted at HCRI with SAS version 9.2 (SAS Institute). All P values are 2-sided and considered significant at the .05 level.

Results
Enrollment in the DAPT Study was conducted between August 2009 and July 2011, with the last follow-up visit conducted in May 2014. Of 2816 enrolled patients treated with BMS, 583 (20.7%) were not eligible for randomization (mainly due to clinical events requiring continuation of DAPT, such as MI or repeat revascularization procedures) after 12 months of follow-up, 546 (19.4%) were eligible but not randomized, and 1687 (59.9%) were randomized (Figure). Of 25 682 total enrolled patients, 5844 (22.8%) were not eligible for randomization after 12 months of follow-up, 8190 (31.9%) were eligible but not randomized, and 11 648 (45.4%) were randomized, with median follow-up of 990 days (interquartile range, 981–990) (eFigure in the Supplement). The most common reason eligible patients were not randomized was withdrawal of consent.
Table 1. Baseline Characteristics of Randomized Patients Treated With Bare Metal Stents

<table>
<thead>
<tr>
<th>No. (%)</th>
<th>Continued Thienopyridine (n = 842)</th>
<th>Received Placebo (n = 845)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>58.9 (10.5)</td>
<td>59.2 (11.1)</td>
</tr>
<tr>
<td>Female sex</td>
<td>215 (25.5)</td>
<td>184 (21.8)</td>
</tr>
<tr>
<td>Nonwhite race</td>
<td>62 (7.5)</td>
<td>61 (7.3)</td>
</tr>
<tr>
<td>Weight, mean (SD), kg</td>
<td>88.0 (18.4)</td>
<td>88.5 (18.8)</td>
</tr>
<tr>
<td>BMI, mean (SD)</td>
<td>29.5 (5.2)</td>
<td>29.6 (5.6)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>181 (21.7)</td>
<td>173 (20.7)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>534 (64.0)</td>
<td>543 (64.6)</td>
</tr>
<tr>
<td>Cigarette smoker</td>
<td>360 (43.3)</td>
<td>350 (43.3)</td>
</tr>
<tr>
<td>Stroke/TIA</td>
<td>43 (5.1)</td>
<td>34 (4.0)</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>35 (4.2)</td>
<td>28 (3.3)</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>35 (4.2)</td>
<td>46 (5.5)</td>
</tr>
<tr>
<td>Prior PCI</td>
<td>150 (17.9)</td>
<td>171 (20.3)</td>
</tr>
<tr>
<td>Prior CABG</td>
<td>50 (6.0)</td>
<td>50 (5.9)</td>
</tr>
<tr>
<td>Prior MI</td>
<td>160 (19.4)</td>
<td>178 (21.5)</td>
</tr>
<tr>
<td>Indication for PCI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI</td>
<td>311 (36.9)</td>
<td>324 (38.3)</td>
</tr>
<tr>
<td>NSTEMI</td>
<td>184 (21.9)</td>
<td>169 (20.0)</td>
</tr>
<tr>
<td>Unstable angina</td>
<td>77 (9.1)</td>
<td>81 (9.6)</td>
</tr>
<tr>
<td>Stable angina</td>
<td>199 (23.6)</td>
<td>198 (23.4)</td>
</tr>
<tr>
<td>Other</td>
<td>71 (8.4)</td>
<td>73 (8.6)</td>
</tr>
<tr>
<td>Any risk factor for stent thrombosis</td>
<td>568 (69.2)</td>
<td>569 (69.0)</td>
</tr>
<tr>
<td>Any clinical</td>
<td>525 (64.0)</td>
<td>521 (63.2)</td>
</tr>
<tr>
<td>Enzyme-positive ACS (STEMI or NSTEMI)</td>
<td>495 (58.8)</td>
<td>493 (58.3)</td>
</tr>
<tr>
<td>Renal insufficiency/failure</td>
<td>28 (3.4)</td>
<td>20 (2.4)</td>
</tr>
<tr>
<td>LVEF &lt;30%</td>
<td>32 (4.0)</td>
<td>29 (3.6)</td>
</tr>
<tr>
<td>Any lesion-related</td>
<td>325 (38.7)</td>
<td>316 (37.5)</td>
</tr>
<tr>
<td>&gt;2 vessels stented</td>
<td>0</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>&gt;2 lesions per vessel</td>
<td>9 (1.1)</td>
<td>8 (1.0)</td>
</tr>
<tr>
<td>Lesion length ≥30 mm</td>
<td>55 (6.5)</td>
<td>56 (6.6)</td>
</tr>
<tr>
<td>Bifurcation lesion side branch ≥2.5 mm</td>
<td>38 (4.5)</td>
<td>34 (4.0)</td>
</tr>
<tr>
<td>In-stent restenosis of a DES</td>
<td>3 (0.4)</td>
<td>6 (0.7)</td>
</tr>
<tr>
<td>Vein bypass graft stented</td>
<td>22 (2.6)</td>
<td>20 (2.4)</td>
</tr>
<tr>
<td>Unprotected left main stented</td>
<td>0</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>Thrombus-containing lesion</td>
<td>243 (28.9)</td>
<td>219 (25.9)</td>
</tr>
<tr>
<td>Prior brachytherapy</td>
<td>1 (0.1)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>North America</td>
<td>509 (60.5)</td>
<td>519 (61.4)</td>
</tr>
<tr>
<td>Europe</td>
<td>304 (36.1)</td>
<td>300 (35.5)</td>
</tr>
<tr>
<td>Australia or New Zealand</td>
<td>29 (3.4)</td>
<td>26 (3.1)</td>
</tr>
<tr>
<td>Thienopyridine drug at randomization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>730 (86.7)</td>
<td>732 (86.6)</td>
</tr>
<tr>
<td>Prasugrel</td>
<td>112 (13.3)</td>
<td>113 (13.4)</td>
</tr>
<tr>
<td>No. of treated lesions, mean (SD)</td>
<td>1.2 (0.4)</td>
<td>1.2 (0.4)</td>
</tr>
</tbody>
</table>

(continued)
Baseline characteristics of randomized patients treated with BMS were similar between the groups (Table 1). While the same inclusion and exclusion criteria were applied to all enrolled patients, DES- and BMS-treated patients differed according to clinical and procedural characteristics (eTable 2 in the Supplement). Patients treated with DES were more likely to have a history of diabetes mellitus (30.6% vs 21.2%, \( P < .001 \)), hypertension, and previous PCI and to have longer lesions, with smaller reference vessel diameter, while patients treated with BMS were more likely to present with ST-elevation MI (STEMI, 37.6% vs 10.5%, \( P < .001 \)) or non-STEMI (20.9% vs 15.5%, \( P < .001 \)) and were more likely to have thrombus noted in the treated lesion. The baseline characteristics of the randomized patients treated with DES have been previously published.\(^4\) Baseline characteristics of all randomized patients were similar between the randomly assigned treatment groups (Table 2 in the Supplement). Predefined risk factors for stent thrombosis were present in 54% of patients in each randomly assigned treatment group.

### Effect of Continued Thienopyridine Therapy Among Patients Treated With BMS

Among randomized patients treated with BMS, the cumulative incidence of stent thrombosis and MACCE were 0.5% vs 1.1% (HR, 0.49; 95% CI, 0.15-1.64; log-rank \( P = .24 \)) and 4.0% vs 4.7% (HR, 0.92; 95% CI, 0.57-1.47; log-rank \( P = .72 \)), respectively, for continued thienopyridine vs placebo at 12 to 30 months after the index procedure (Table 2). Moderate or severe GUSTO bleeding events occurred in 2.03% vs 0.90% among patients treated with BMS randomized to continued thienopyridine vs placebo (\( P = .07 \)); BARC type 2, 3, or 5 bleeding events occurred in 4.56% vs 1.80%, respectively (\( P = .002 \)). Severe bleeding was uncommon, fatal bleeding events (BARC type 5) were rare, and rates were not different between treatment groups (Table 2).

The results comparing continued thienopyridine vs placebo in the cohort treated with DES have been reported previously and demonstrated significant reductions in study co-primary end points of stent thrombosis (0.4% vs 1.4%, respectively; HR, 0.29; 95% CI, 0.17-0.48) and MACCE (4.3% vs 5.9%, respectively; HR, 0.71; 95% CI, 0.59-0.85) (driven by a reduction in both stent-related and non-stent-related MI) (Table 3). An increase in moderate/severe bleeding events was observed (2.5% vs 1.6%, respectively; \( P = .001 \)), and a difference in all-cause mortality rate that was not statistically significant was seen (2.0% vs 1.5%; \( P = .052 \)), yet mortality was infrequently related to bleeding (0.15% vs 0.09% with fatal bleeding, \( P = .38 \), and 0.22% vs 0.06% with bleeding-related mortality within the full 33-month follow-up, \( P = .057 \)).\(^4\)

### Consistency of Effects of Continued Thienopyridine Across BMS- and DES-Treated Patients

The prespecified analysis of the effect of continued thienopyridine found nonsignificant interactions between randomized BMS- and DES-treated patients for both stent thrombosis (HR, 0.49 vs 0.29; interaction \( P = .42 \)) and MACCE (HR, 0.92 vs 0.71; interaction \( P = .32 \)) (Table 3). Among all randomized patients, the co-primary effectiveness end points of stent thrombosis (0.41% vs 1.32%; HR, 0.31; 95% CI, 0.19 to 0.50; \( P < .001 \)) and MACCE (4.29% vs 5.74%; HR, 0.73; 95% CI, 0.62 to 0.87; \( P < .001 \)) were reduced by continued thienopyridine vs placebo, respectively (Table 4). The reduction in stent thrombosis was

---

Table 1. Baseline Characteristics of Randomized Patients Treated With Bare Metal Stents\(^a\) (continued)

<table>
<thead>
<tr>
<th>No. (%)</th>
<th>Continued Thienopyridine (( n = 842 ))</th>
<th>Received Placebo (( n = 845 ))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lesion characteristics, No. (%)(^a)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treated vessel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left main</td>
<td>0</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>LAD</td>
<td>308 (31.6)</td>
<td>306 (30.9)</td>
</tr>
<tr>
<td>RCA</td>
<td>437 (44.8)</td>
<td>452 (45.6)</td>
</tr>
<tr>
<td>Circumflex</td>
<td>206 (21.1)</td>
<td>207 (20.9)</td>
</tr>
<tr>
<td>Venous graft</td>
<td>24 (2.5)</td>
<td>25 (2.5)</td>
</tr>
<tr>
<td>Arterial graft</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Modified ACC/AHA lesion class B2 or C</td>
<td>440 (47.6)</td>
<td>450 (47.8)</td>
</tr>
</tbody>
</table>

\(^a\) Abbreviations: ACC, American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart Association; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CABG, coronary artery bypass graft procedure; DES, drug-eluting stent; LAD, left anterior descending; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSTEMI, non-ST elevation MI; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEM, ST-elevation MI; TIA, transient ischemic attack.

\(^b\) Race was self-reported.

\(^c\) This category included unstable angina without reported elevation of cardiac enzymes.

\(^d\) A total of 975 lesions were treated in the continued thienopyridine group and 991 in the placebo group.

\(^e\) The definitions of class B2 and class C lesions according to the modified ACC/AHA criteria.\(^2\)

---

**Copyright 2015 American Medical Association. All rights reserved.**
largely explained by a reduction in definite stent thrombosis, and the reduction in MACCE was largely explained by a 48% relative reduction (1.83% absolute) in MI. Significant reductions were observed in MI related to stent thrombosis (0.38% vs 1.28%, HR, 0.29; 95% CI, 0.18 to 0.48; \( P < .001 \)) as well as MI not related to stent thrombosis (1.65% vs 2.75%, HR, 0.65; 95% CI, 0.50 to 0.84; \( P < .001 \)). In contrast, there was an increased incidence of severe/moderate bleeding events (2.45% vs 1.71%, risk difference, 0.74; 95% CI, 0.50 to 0.98; \( P = .001 \)) largely explained by the relative increase in moderate bleeding (1.65% vs 0.96%, risk difference, 0.70; 95% CI, 0.27 to 1.12; \( P = .001 \)). Similarly, BARC type 2, 3, or 5 bleeding events were significantly increased in the continued thienopyridine treatment group (5.44% vs 2.78%; HR, 2.65; 95% CI, 1.91 to 3.40; \( P < .001 \)), yet fatal bleeding events (BARC type 5) were rare (0.13% vs 0.09%; \( P = .58 \) (Table 4).

**Discussion**

Among patients undergoing coronary stent placement with BMS and who tolerated 12 months of thienopyridine, con-
Continuing thienopyridine for an additional 18 months compared with placebo did not result in statistically significant differences in rates of stent thrombosis, MACCE, or moderate or severe bleeding. However, limitations in sample size and power make definitive conclusions regarding DAPT treatment duration effects within BMS difficult. While fewer patients treated with BMS were enrolled to allow a powered comparison of continued duration of therapy independent of stent type, an adequately powered randomized BMS cohort would practically not feasible. An adequate number of patients require approximately 8000 additional patients, which was beyond the target lesion at 1 year with continued thienopyridine therapy (2.0% vs 1.5%, \( P = .052 \)) that was observed in the cohort treated with DES was not evident among randomized patients treated with BMS (1.0% vs 1.2%, \( P = .83 \)).

The lack of apparent treatment interaction between DES and BMS supports the combined analysis of treatment effects of continued duration of therapy independent of stent type. Among the combined BMS and DES cohort, the reductions in stent thrombosis and MACCE were 69% and 27%, respectively, in patients continuing thienopyridine therapy together with aspirin. Fifty percent of the MIs prevented by continued DAPT were not related to stent thrombosis. These ischemic event benefits were balanced by a 67% relative increase in moderate or severe bleeding.

The major limitation of the BMS randomized comparison of DAPT duration is small sample size and lack of power, which limits the interpretability of the findings. However, an adequately powered randomized BMS cohort would require approximately 8000 additional patients, which was practically not feasible. An adequate number of patients treated with BMS were enrolled to allow a powered comparison of stent thrombosis and MACCE rates with patients

### Table 4. Ischemic and Bleeding Outcomes in All Randomized Patients (Treated With Bare Metal or Drug-Eluting Stent) Comparing Continued Thienopyridine vs Placebo

<table>
<thead>
<tr>
<th>Ischemic Outcomes</th>
<th>Patients, No. (%)a</th>
<th>Hazard Ratio (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stent thrombosis</td>
<td>Continued Thienopyridine (n = 5862)</td>
<td>0.31 (0.19 to 0.50)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Definite</td>
<td>23 (0.41)</td>
<td>74 (1.32)</td>
<td></td>
</tr>
<tr>
<td>Probable</td>
<td>4 (0.09)</td>
<td>5 (0.12)</td>
<td></td>
</tr>
<tr>
<td>MACCE (death, MI, stroke)</td>
<td>244 (4.29)</td>
<td>323 (5.74)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Death, all cause</td>
<td>106 (1.87)</td>
<td>84 (1.50)</td>
<td>.07</td>
</tr>
<tr>
<td>MI</td>
<td>121 (2.15)</td>
<td>223 (3.98)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Related to stent thrombosis</td>
<td>21 (0.38)</td>
<td>72 (1.28)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Not related to stent thrombosis</td>
<td>104 (1.84)</td>
<td>154 (2.75)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Stroke (total)</td>
<td>43 (0.76)</td>
<td>48 (0.86)</td>
<td>.42</td>
</tr>
<tr>
<td>Ischemic</td>
<td>28 (0.50)</td>
<td>39 (0.70)</td>
<td>.16</td>
</tr>
<tr>
<td>Hemorrhagic</td>
<td>14 (0.25)</td>
<td>9 (0.16)</td>
<td>.53</td>
</tr>
<tr>
<td>Type uncertain</td>
<td>1 (0.02)</td>
<td>1 (0.02)</td>
<td>&gt;.99</td>
</tr>
</tbody>
</table>

### Bleeding Complications

<table>
<thead>
<tr>
<th>Bleeding Complications</th>
<th>(n = 5500)</th>
<th>(n = 5425)</th>
<th>Risk Difference, % Points (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GUSTO severe or moderate</td>
<td>135 (2.45)</td>
<td>80 (1.47)</td>
<td>0.98 (0.46 to 1.50) &lt;.001</td>
</tr>
<tr>
<td>Severe</td>
<td>44 (0.80)</td>
<td>29 (0.53)</td>
<td>0.27 (−0.04 to 0.57) .09</td>
</tr>
<tr>
<td>Moderate</td>
<td>91 (1.65)</td>
<td>52 (0.96)</td>
<td>0.70 (0.27 to 1.12) .001</td>
</tr>
<tr>
<td>BARC type</td>
<td>299 (5.44)</td>
<td>151 (2.78)</td>
<td>2.65 (1.91 to 3.40) &lt;.001</td>
</tr>
<tr>
<td>Type 2</td>
<td>167 (3.04)</td>
<td>79 (1.46)</td>
<td>1.58 (1.03 to 2.13) &lt;.001</td>
</tr>
<tr>
<td>Type 3</td>
<td>138 (2.51)</td>
<td>74 (1.36)</td>
<td>1.15 (0.63 to 1.66) &lt;.001</td>
</tr>
<tr>
<td>Type 5 (fatal)</td>
<td>7 (0.13)</td>
<td>5 (0.09)</td>
<td>0.04 (−0.09 to 0.16) .58</td>
</tr>
</tbody>
</table>

Abbreviations: BARC, Bleeding Academic Research Consortium; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries; MACCE, major adverse cardiovascular and cerebrovascular events; MI, myocardial infarction.

a Patients were randomized to continue receiving thienopyridine or to receive placebo plus aspirin 12 months after receiving a bare metal stent. The effectiveness endpoints, stent thrombosis and MACCE, are shown over the primary analysis period, eg, 12-30 months after enrollment. Percentages are Kaplan-Meier estimates. For the safety end point of GUSTO severe or moderate bleeding, patients whose last contact date was >510 days after randomization or who experienced any adjudicated bleeding outcome at or before 540 days were included. See eTable 3 in the Supplement for GUSTO and BARC definitions.
treated with DES, the results of which have been presented separately. 18 In this context, the design of the BMS randomized comparison was to evaluate for consistency or heterogeneity compared with the DES treatment effect in an exploratory fashion, rather than to be powered for a separate, independent analysis. Nonetheless, the BMS cohort sample size exceeds that of prior randomized BMS cohorts evaluating duration of antiplatelet therapy and is similar in size to many prior randomized trials of DAPT duration in DES. 5,19–22 Although similar inclusion criteria were required of BMS- and DES-treated patients, there were systematic differences between BMS- and DES-treated patients, with a higher frequency of MI presentation before the index PCI procedure for patients treated with BMS and a higher prevalence of restenosis risk factors for patients treated with DES. Nevertheless, each cohort was balanced across randomized treatment groups as expected according to the stratified randomization.

Conclusions

Among patients undergoing coronary stent placement with BMS who tolerated 12 months of thienopyridine and aspirin therapy without major bleeding, continuing thienopyridine therapy in addition to aspirin beyond 12 months did not result in statistically significant differences in rates of stent thrombosis, MACCE, or moderate or severe bleeding. However, the BMS subset may have been underpowered to determine such differences.

ARTICLE INFORMATION

Author Affiliations: The Christ Hospital Heart and Vascular Center, Cincinnati, Ohio (Kereiakes); Lindner Research Center, Cincinnati, Ohio (Kereiakes); Harvard Clinical Research Institute, Boston, Massachusetts (Yeh, MASSaro, Driscoll-Shempp, Cutlip, MAuri); Massachusetts General Hospital, Boston (Yeh); Boston University, Boston, Massachusetts (Massaro); Beth Israel Deaconess Medical Center, Boston, Massachusetts (Cutlip); Université Paris-Diderot, Paris, France (Steg); Département Hôpital-Universitaire Fira, Hôpital Bichat, Paris, France (Steg); National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, United Kingdom (Steg); Department of Cardiovascular Sciences, University of Leicester and National Institute of Health Research Leicester Cardiovascular Biomedical Research Unit, University Hospitals of Leicester, Leicester, United Kingdom (Gershlick); Vivantes Neukoelln Medical Center, Berlin, Germany (Darius); Monash Heart, Victoria, Australia (Meredith); Mercy Hospital, Auckland, New Zealand (Ormiston); Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada (Tanguay); Bern University Hospital, Bern, Switzerland (Windkecker); Lenox Hill Hospital, New York, New York (Garratt); Piedmont Heart Institute, Atlanta, Georgia (Kandzari); Stanford University, Stanford, California (Lee); University Hospitals Case Medical Center, Cleveland, Ohio (Simon); Heart Institute, Cluj-Napoca, Romania (lancu); Jan Pawel II Hospital Krakow, Krakow, Poland (trebacz); Brigham and Women’s Hospital, Boston, Massachusetts (Mauri); Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania (lancu).

Author Contributions: Drs Kereiakes, Massaro, and Mauri had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Kereiakes, Yeh, Massaro, Cutlip, Mauri.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Kereiakes, Yeh, Mauri.

Critical revision of the manuscript for important intellectual content: Kereiakes, Yeh, Massaro, Driscoll-Shempp, Cutlip, Steg, Gershlick, Darius, Meredith, Ormiston, Tanguay, Windkecker, Garratt, Kandzari, Lee, Simon, Iancu, Trebacz, Mauri.

Statistical analysis: Massaro, Mauri.

Obtained funding: Mauri.

Administrative, technical, or material support: Driscoll-Shempp, Cutlip, Mauri.

Study supervision: Driscoll-Shempp, Mauri.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Yeh reported having received personal fees from Abbott Vascular, personal fees and nonfinancial support from Harvard Clinical Research Institute, and personal fees from Gilead Sciences. Dr Massaro reported having received personal fees from Harvard Clinical Research Institute. Dr Cutlip reported having received support from Medtronic, Boston Scientific, Cordis, and Abbott Vascular and grants from the National Heart, Lung, and Blood Institute. Dr Steg reported having received personal fees from Amarin, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Sharpe and Dohme, Novartis, Otsuka, Pfizer, Roche, Medtronic, Vivus, The Medicines Company, and Orexigen and grants and personal fees from sanofi-aventis and Servier. Dr Gershlick reported having received personal fees from Medtronic and Abbott and grants from The Medicines Company. Dr Darius reported having received grants from Harvard Clinical Research Institute. Dr Meredith reported having received support from Boston Scientific and Medtronic. Dr Tanguay reported having received personal fees and/or other support from Abbott Vascular, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Roche, sanofi-aventis, Servier, Ikaria, and Merck. Dr Windkecker reported having received grants from St Jude Medical, Biotronik, The Medicines Company, Abbott, Medtronic, and Edwards Lifesciences and personal fees from AstraZeneca, Eli Lilly, Abbott, Biosensors, Biotronik, and Bayer. Dr Garratt reported having received grants from Boston Scientific, Abbott Vascular, and CelONova and personal fees or other support from Boston Scientific, The Medicines Company, Abbott Vascular, Infarct Reduction Technologies, Guided Delivery Systems, and Daiichi-Sankyo/Lilly. Dr Kandzari reported having received grants from Medtronic Cardiovascular, Abbott Vascular, Boston Scientific, and Biotronik and personal fees from Micell Technologies, Medtronic Cardiovascular, and Boston Scientific. Dr Lee reported having received grants from Boston Scientific and personal fees from Boston Scientific and Medtronic. Dr Simon reported having received other support from Cordis John Johnson & Johnson and personal fees from Cordis Johnson & Johnson and Medtronic Vascular. Dr Mauri reported having received grants from Abbott, Boston Scientific, Medtronic, Cordis, Eli Lilly, Daiichi Sankyo, Bristol-Myers Squibb, sanofi-aventis, and Biotronik and personal fees from Medtronic, St Jude, and Biotronik. No other disclosures were reported.

Funding/Support: The study was sponsored by the Harvard Clinical Research Institute (HCRI) and funded by Abbott, Boston Scientific, Cordis, Medtronic, Bristol-Myers Squibb/Sanoﬁ Pharmaceuticals Partnership, Eli Lilly, and Daiichi Sankyo and the US Department of Health and Human Services (R01FD003870-01).

Role of the Funder/Sponsor: The funding manufacturers and US Food and Drug Administration had input on the study design and conduct of the study. The HCRI oversaw the collection, management, and analysis of the data; the study authors were responsible for interpretation of the data, preparation of the manuscript, and the decision to submit the manuscript for publication.

Previous Presentation: Results were presented in an abstract and in a presentation at the American Heart Association Scientific Sessions, Chicago, Illinois, November 18, 2014.

Additional Contributions: We thank the other investigators, the staff, and the participants of the DAPT Study for their valuable contributions. We wish to acknowledge Joanna Suomi, MSc, for assistance editing and formatting the manuscript and Wen-Hua Hsieh, PhD, for assistance with statistical analysis. Both are employed by Harvard Clinical Research Institute and were compensated for their contributions.

Correction: This article was corrected online April 28, 2015, for errors in describing the prespecified analyses and July 5, 2016, to add an institution to an author’s affiliation.

REFERENCES


Antiplatelet Therapuduration After Stent Placement

Original Investigation Research

randomized,double-blindtrialtoassessthe
therapystudy,aprospective,multicenter,
Rationaleanddesignofthedualantiplatelet
8
N Engl J Med

 Investigators.Twelveor30monthsofdual
antiplatelettherapyafterdrug-elutingstents.
4
494-502.

ST-segmentelevation.
3

Task Force on Myocardial Revascularization of the
European Society of Cardiology (ESC) and the
European Association for Cardio-Thoracic Surgery
(EACTS), developed with the special contribution of
the European Association of Percutaneous
Cardiovascular Interventions (EAPCI). Eur Heart J.
2015;36(37):2541-2619.
1

Yusuf S, Zhao F, Mehta SR, Chrolavicius S,
Tognoni G, Fox KK; Clopidogrel in Unstable Angina
to Prevent Recurrent Events Trial Investigators.
Effects of clopidogrel in addition to aspirin in
patients with acute coronary syndromes without
494-502.

Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study
Investigators. Twelve or 30 months of dual
antiplatelet therapy after drug-eluting stents.

Valgimigli M, Campo G, Monti M, et al; Prolonging
Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study
(PRODIGY) Investigators. Short-versus long-term
duration of dual-antiplatelet therapy after coronary
stenting: a randomized multicenter trial. Circulation.

Badheka AO, Arora S, Panaich SS, et al. Impact
on in-hospital outcomes with drug-eluting stents
versus bare-metal stents (from 665,804

Douglas PS, Brennan JM, Anstrom KJ, et al.
Clinical effectiveness of coronary stents in elderly
persons: results from 262,700 Medicare patients in
the American College of Cardiology-National
Cardiovascular Data Registry. J Am Coll Cardiol.

Mauri L, Kereiakes DJ, Normand SL, et al. Rationale
and design of the dual antiplatelet therapy
study, a prospective, multicenter, randomized, double-blind trial to assess the
effectiveness and safety of 12 versus 30 months of
dual antiplatelet therapy in subjects undergoing
percutaneous coronary intervention with either
drug-eluting stent or bare metal stent placement
for the treatment of coronary artery lesions. Am

Cutlip DE, Windecker S, Mehran R, et al; Academic
Research Consortium. Clinical end points in
coronary stent trials: a case for standardized

An international randomized trial comparing
four thrombolytic strategies for acute myocardial
1993;329(10):673-682.

bleeding definitions for cardiovascular clinical trials:
a consensus report from the Bleeding Academic
2736-2747.

Ellis SG, VANDERMAEL MG, Cowley MJ, et al; Multivessel Angioplasty

long-term (15 to 20 years) clinical and angiographic
outcome after coronary bare metal stent
468-475.

Cutlip DE, Chhabra AG, Baim DS, et al. Beyond
restenosis: five-year clinical outcomes from
second-generation coronary stent trials. Circulation.

of target lesion and non-target lesion cardiac events
on 5-year clinical outcomes after sirolimus-eluting
or bare-metal stenting. JACC Cardiovasc Interv.

Takano M, Yamamoto M, Mizuno K. Two cases
of coronary stent thrombosis very late after
bare-metal stenting. JACC Cardiovasc Interv.

Chen MS, John JM, Chew DP, Lee DS, Ellis SG,
Bhatt DL. Bare metal stent restenosis is not a
benign clinical entity. Am Heart J. 2006;151(6):
1260-1264.

Kereiakes DJ, Yeh RW, Massaro JM, et al.
Comparison of ischemic events after drug-eluting
stents or bare metal stents in subjects receiving
dual antiplatelet therapy: results from the
randomized Dual Antiplatelet Therapy Study

Six-month versus 24-month dual antiplatelet
therapy after implantation of drug eluting stents in
patients non-resistant to aspirin: ITALIC, a
randomized multicenter trial [published online
jacc.2014.11.008.

Gwon HC, Hahn JY, Park KW, et al. Six-month
versus 12-month dual antiplatelet therapy after
implantation of drug-eluting stents: the Efficacy
of Xenon/Primus Versus Cypher to Reduce Late
Loss After Stenting (EXCELLENT) randomized,

Feres F, Costa RA, Abizaid A, et al; OPTIMIZE
Trial Investigators. Three vs twelve months of
dual antiplatelet therapy after zotarolimus-eluting
stents: the OPTIMIZE randomized trial. JAMA.
2013;310(23):2510-2522.

Second-generation drug-eluting stent implantation
followed by 6- versus 12-month dual antiplatelet
therapy: the SECURITY randomized clinical trial.

Copyright 2015 American Medical Association. All rights reserved.